Table 3.
Clinicopathological characteristics and survival of 56 MIBC patients.
| Whole population |
Disease-free survival |
Overall survival |
|||
|---|---|---|---|---|---|
| Number of patients (%) | Number of events (%)a | p-value* | Number of events (%)b | p-value* | |
| Total population | 56 (100.0) | 36 (64.3) | 34 (60.7) | ||
| Age (years) | |||||
| ≥60 | 40 (71.4) | 30 (83.3) | 0.0082 | 30 (88.2) | 0.0005 |
| <60 | 16 (28.6) | 6 (16.7) | 4 (11.8) | ||
| Sex | |||||
| Male | 42 (75.0) | 24 (66.7) | 0.053 (NS) | 26 (76.5) | 0.75 (NS) |
| Female | 14 (25.0) | 12 (33.3) | 8 (23.5) | ||
| Smoking statusc | |||||
| Non-smoker | 9 (18.0) | 7 (23.3) | 0.41 (NS) | 7 (24.1) | 0.34 (NS) |
| Smoker | 41 (82.0) | 23 (76.7) | 22 (75.9) | ||
| History of NMIBC | |||||
| No | 35 (62.5) | 21 (58.3) | 0.39 (NS) | 20 (58.8) | 0.48 (NS) |
| Yes | 21 (37.5) | 15 (41.7) | 14 (41.2) | ||
| Associated pTis | |||||
| No | 50 (89.3) | 34 (94.4) | 0.17 (NS) | 32 (94.1) | 0.20 (NS) |
| Yes | 6 (10.7) | 2 (5.6) | 2 (5.9) | ||
| Tumor stage | |||||
| T2 | 19 (33.9) | 11 (30.6) | 0.47 (NS) | 8 (23.5) | 0.041 |
| ≥T3 | 37 (66.1) | 25 (69.4) | 26 (76.5) | ||
| Lymph node statusd | |||||
| N- | 35 (63.6) | 18 (51.4) | 0.013 | 17 (50.0) | 0.0075 |
| N+ | 20 (36.4) | 17 (48.6) | 17 (50.0) | ||
| FGFR3 status | |||||
| Mutated | 6 (10.7) | 4 (11.1) | >0.99 (NS) | 4 (11.8) | >0.99 (NS) |
| Not mutated | 50 (89.3) | 32 (88.9) | 30 (88.2) | ||
| PIK3CA status | |||||
| Mutated | 6 (10.7) | 2 (5.6) | 0.17 (NS) | 2 (5.9) | 0.20 (NS) |
| Not mutated | 50 (89.3) | 34 (94.4) | 32 (94.1) | ||
*Chi2 test, Chi2 test with Yates’ correction or Fisher test if appropriate
NS: not significant
afirst recurrence (local or metastatic)
bdeath
cdata available for 50 patients
ddata available for 55 patients